These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 16505111)

  • 1. An oncolytic adenovirus expressing soluble transforming growth factor-beta type II receptor for targeting breast cancer: in vitro evaluation.
    Wang ZG; Zhao W; Ramachandra M; Seth P
    Mol Cancer Ther; 2006 Feb; 5(2):367-73. PubMed ID: 16505111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapy.
    Hu Z; Robbins JS; Pister A; Zafar MB; Zhang ZW; Gupta J; Lee KJ; Newman K; Yun CO; Guise T; Seth P
    Cancer Gene Ther; 2010 Apr; 17(4):235-43. PubMed ID: 19798122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-beta receptor II and human immunoglobulin Fc for breast cancer therapy.
    Seth P; Wang ZG; Pister A; Zafar MB; Kim S; Guise T; Wakefield L
    Hum Gene Ther; 2006 Nov; 17(11):1152-60. PubMed ID: 17032151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-β receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model.
    Hu Z; Zhang Z; Guise T; Seth P
    Hum Gene Ther; 2010 Nov; 21(11):1623-9. PubMed ID: 20712434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host.
    Zhang Z; Hu Z; Gupta J; Krimmel JD; Gerseny HM; Berg AF; Robbins JS; Du H; Prabhakar B; Seth P
    Cancer Gene Ther; 2012 Sep; 19(9):630-6. PubMed ID: 22744210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic adenovirus expressing soluble TGFβ receptor II-Fc-mediated inhibition of established bone metastases: a safe and effective systemic therapeutic approach for breast cancer.
    Hu Z; Gerseny H; Zhang Z; Chen YJ; Berg A; Zhang Z; Stock S; Seth P
    Mol Ther; 2011 Sep; 19(9):1609-18. PubMed ID: 21712815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of in vivo tumorigenicity of rat hepatoma cell line KDH-8 cells by soluble TGF-beta receptor type II.
    Zhao W; Kobayashi M; Ding W; Yuan L; Seth P; Cornain S; Wang J; Okada F; Hosokawa M
    Cancer Immunol Immunother; 2002 Sep; 51(7):381-8. PubMed ID: 12192538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor β Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models.
    Xu W; Yang Y; Hu Z; Head M; Mangold KA; Sullivan M; Wang E; Saha P; Gulukota K; Helseth DL; Guise T; Prabhkar BS; Kaul K; Schreiber H; Seth P
    Hum Gene Ther; 2020 Aug; 31(15-16):863-880. PubMed ID: 32394753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy.
    Yang Y; Xu W; Peng D; Wang H; Zhang X; Wang H; Xiao F; Zhu Y; Ji Y; Gulukota K; Helseth DL; Mangold KA; Sullivan M; Kaul K; Wang E; Prabhakar BS; Li J; Wu X; Wang L; Seth P
    Hum Gene Ther; 2019 Sep; 30(9):1117-1132. PubMed ID: 31126191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic adenovirus targeting TGF-β enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer.
    Li Y; Xiao F; Zhang A; Zhang D; Nie W; Xu T; Han B; Seth P; Wang H; Yang Y; Wang L
    Cell Immunol; 2020 Feb; 348():104041. PubMed ID: 31983398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model.
    Hu Z; Gupta J; Zhang Z; Gerseny H; Berg A; Chen YJ; Zhang Z; Du H; Brendler CB; Xiao X; Pienta KJ; Guise T; Lee C; Stern PH; Stock S; Seth P
    Hum Gene Ther; 2012 Aug; 23(8):871-82. PubMed ID: 22551458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic Adenovirus rAd.DCN Inhibits Breast Tumor Growth and Lung Metastasis in an Immune-Competent Orthotopic Xenograft Model.
    Zhao H; Wang H; Kong F; Xu W; Wang T; Xiao F; Wang L; Huang D; Seth P; Yang Y; Wang H
    Hum Gene Ther; 2019 Feb; 30(2):197-210. PubMed ID: 30032645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Construction of recombinant adenovirus vector expressing extracellular domain of TbetaR-II-RANTES fusion gene and its anti-tumor effects].
    Wang XD; Liu H; Cao S; Li H; Ren XB; Hao XS
    Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):405-10. PubMed ID: 17974270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic Delivery of an Oncolytic Adenovirus Expressing Decorin for the Treatment of Breast Cancer Bone Metastases.
    Yang Y; Xu W; Neill T; Hu Z; Wang CH; Xiao X; Stock SR; Guise T; Yun CO; Brendler CB; Iozzo RV; Seth P
    Hum Gene Ther; 2015 Dec; 26(12):813-25. PubMed ID: 26467629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory effect of a soluble transforming growth factor beta type II receptor on the activation of rat hepatic stellate cells in primary culture.
    Cui X; Shimizu I; Lu G; Itonaga M; Inoue H; Shono M; Tamaki K; Fukuno H; Ueno H; Ito S
    J Hepatol; 2003 Nov; 39(5):731-7. PubMed ID: 14568254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542.
    Laping NJ; Grygielko E; Mathur A; Butter S; Bomberger J; Tweed C; Martin W; Fornwald J; Lehr R; Harling J; Gaster L; Callahan JF; Olson BA
    Mol Pharmacol; 2002 Jul; 62(1):58-64. PubMed ID: 12065755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hexon modification to improve the activity of oncolytic adenovirus vectors against neoplastic and stromal cells in pancreatic cancer.
    Lucas T; Benihoud K; Vigant F; Schmidt CQ; Wortmann A; Bachem MG; Simmet T; Kochanek S
    PLoS One; 2015; 10(2):e0117254. PubMed ID: 25692292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming growth factor beta1 receptor II is downregulated by E1A in adenovirus-infected cells.
    Tarakanova VL; Wold WS
    J Virol; 2003 Sep; 77(17):9324-36. PubMed ID: 12915548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting human breast cancer cells by an oncolytic adenovirus using microRNA-targeting strategy.
    Shayestehpour M; Moghim S; Salimi V; Jalilvand S; Yavarian J; Romani B; Mokhtari-Azad T
    Virus Res; 2017 Aug; 240():207-214. PubMed ID: 28867494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenoviral delivery of dominant-negative transforming growth factor beta type II receptor up-regulates transcriptional repressor SKI-like oncogene, decreases matrix metalloproteinase 2 in hepatic stellate cell and prevents liver fibrosis in rats.
    Marquez-Aguirre A; Sandoval-Rodriguez A; Gonzalez-Cuevas J; Bueno-Topete M; Navarro-Partida J; Arellano-Olivera I; Lucano-Landeros S; Armendariz-Borunda J
    J Gene Med; 2009 Mar; 11(3):207-19. PubMed ID: 19189315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.